{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:40:30Z","timestamp":1793086830529,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris I\u00a0de Recerca","doi-asserted-by":"crossref","award":["2017SGR992"],"award-info":[{"award-number":["2017SGR992"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas [CIBER-EHD], Spain"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Vedolizumab is an anti-\u03b14\u03b27 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the unique mechanisms of action of vedolizumab in UC patients, we compared its effects to those induced by anti-tumour necrosis factor [TNF].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with active UC [endoscopic Mayo score &amp;gt;1] starting vedolizumab [n = 33] or anti-TNF [n = 45] and controls [n = 22] were included. Colon biopsies [at weeks 0, 14 and 46] and blood samples [at weeks 0, 2, 6, 14, 30 and 46] were used for cell phenotyping, transcriptional analysis [qPCR], and to measure receptor occupancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Vedolizumab, in contrast to anti-TNF, significantly reduced the proportion of \u03b14\u03b27+ cells within intestinal T subsets while preserving the percentage of \u03b14\u03b27+ plasma cells. The marked decrease in \u03b14\u03b27 did not change the percentage of colonic \u03b1E\u03b27+ cells [at 46 weeks]. Both vedolizumab and anti-TNF significantly downregulated inflammation-related genes in the colon of responders [Mayo score &amp;lt; 2]. Moreover, both treatments significantly decreased the percentage of intestinal, but not blood, total lymphocytes [T and plasma cells], as well as the proportion of \u03b14\u03b21+ cells within intestinal T lymphocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data show that while vedolizumab and anti-TNF block two unrelated targets, they induce remarkably similar effects. On the other hand, vedolizumab\u2019s unique mechanism of action relies on blocking intestinal trafficking of \u03b14\u03b27 T cells, despite effectively binding to B and plasma cells that express \u03b14\u03b27.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa178","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T15:12:49Z","timestamp":1599837169000},"page":"441-452","source":"Crossref","is-referenced-by-count":30,"title":["Dissecting Common and Unique Effects of Anti-\u03b14\u03b27 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis"],"prefix":"10.1093","volume":"15","author":[{"given":"Marisol","family":"Veny","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garrido-Trigo","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M","family":"Corraliza","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Masamunt","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bassolas-Molina","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Esteller","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arroyes","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Trist\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital Universitari Mutua Terrassa, CIBERehd, Department of Gastroenterology, Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Fern\u00e1ndez-Clotet","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Ord\u00e1s","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricart","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esteve","sequence":"additional","affiliation":[{"name":"Hospital Universitari Mutua Terrassa, CIBERehd, Department of Gastroenterology, Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-2907","authenticated-orcid":false,"given":"Azucena","family":"Salas","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Gastroenterology Department, Hospital Clinic of Barcelona, Barcelona, Spain; Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"2021031010464888600_CIT0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0002","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2021031010464888600_CIT0003","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2021031010464888600_CIT0004","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"2021031010464888600_CIT0005","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"2021031010464888600_CIT0006","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2021031010464888600_CIT0007","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"2021031010464888600_CIT0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2021031010464888600_CIT0009","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2021031010464888600_CIT0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4049\/jimmunol.151.2.717","article-title":"Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism","volume":"151","author":"Schweighoffer","year":"1993","journal-title":"J Immunol"},{"key":"2021031010464888600_CIT0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J Immunol"},{"key":"2021031010464888600_CIT0012","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.4049\/jimmunol.151.5.2471","article-title":"Alpha 4 beta 7 integrin mediates B cell binding to fibronectin and vascular cell adhesion molecule-1. Expression and function of alpha 4 integrins on human B lymphocytes","volume":"151","author":"Postigo","year":"1993","journal-title":"J Immunol"},{"key":"2021031010464888600_CIT0013","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1189\/jlb.68.6.807","article-title":"Expression of alpha4beta7 and E-selectin ligand by circulating memory B cells: implications for targeted trafficking to mucosal and systemic sites","volume":"68","author":"Rott","year":"2000","journal-title":"J Leukoc Biol"},{"key":"2021031010464888600_CIT0014","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-3083.1995.tb03709.x","article-title":"Human intestinal B-cell blasts and plasma cells express the mucosal homing receptor integrin alpha 4 beta 7","volume":"42","author":"Farstad","year":"1995","journal-title":"Scand J Immunol"},{"key":"2021031010464888600_CIT0015","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2008-04-153544","article-title":"Blood-borne human plasma cells in steady state are derived from mucosal immune responses","volume":"113","author":"Mei","year":"2009","journal-title":"Blood"},{"key":"2021031010464888600_CIT0016","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI119286","article-title":"Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses","volume":"99","author":"Quiding-J\u00e4rbrink","year":"1997","journal-title":"J Clin Invest"},{"key":"2021031010464888600_CIT0017","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gutjnl-2018-316772","article-title":"Non-classical monocyte homing to the gut via \u03b14\u03b27 integrin mediates macrophage-dependent intestinal wound healing","volume":"69","author":"Schleier","year":"2020","journal-title":"Gut"},{"key":"2021031010464888600_CIT0018","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ibd.21266","article-title":"Effect of \u03b14\u03b27 blockade on intestinal lymphocyte subsets and lymphoid tissue development","volume":"16","author":"Wang","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2021031010464888600_CIT0019","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"2021031010464888600_CIT0020","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"2021031010464888600_CIT0021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"key":"2021031010464888600_CIT0022","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/382366a0","article-title":"Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue","volume":"382","author":"Wagner","year":"1996","journal-title":"Nature"},{"key":"2021031010464888600_CIT0023","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"2021031010464888600_CIT0024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2567.1996.d01-727.x","article-title":"Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue","volume":"89","author":"Farstad","year":"1996","journal-title":"Immunology"},{"key":"2021031010464888600_CIT0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021031010464888600_CIT0026","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4049\/jimmunol.1701150","article-title":"Integrin \u03b14\u03b27 blockade preferentially impacts CCR6+ lymphocyte subsets in blood and mucosal tissues of naive rhesus macaques","volume":"200","author":"Calenda","year":"2018","journal-title":"J Immunol"},{"key":"2021031010464888600_CIT0027","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2021031010464888600_CIT0028","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of candidate biomarkers associated with response to vedolizumab in inflammatory bowel disease","volume":"63","author":"Boden","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2021031010464888600_CIT0029","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/mabs.26392","article-title":"In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes","volume":"5","author":"Wyant","year":"2013","journal-title":"MAbs"},{"key":"2021031010464888600_CIT0030","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3389\/fimmu.2018.01700","article-title":"Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases","volume":"9","author":"Rath","year":"2018","journal-title":"Front Immunol"},{"key":"2021031010464888600_CIT0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fphar.2019.00039","article-title":"Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease","volume":"10","author":"Lichnog","year":"2019","journal-title":"Front Pharmacol"},{"key":"2021031010464888600_CIT0032","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ibd\/izy307","article-title":"Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis","volume":"25","author":"Battat","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2021031010464888600_CIT0033","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1136\/gutjnl-2016-312439","article-title":"Blockade of \u03b1E\u03b27 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo","volume":"66","author":"Zundler","year":"2017","journal-title":"Gut"},{"key":"2021031010464888600_CIT0034","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med"},{"key":"2021031010464888600_CIT0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","article-title":"Intestinal T cell profiling in inflammatory bowel disease: linking t cell subsets to disease activity and disease course","volume":"12","author":"Smids","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0036","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.4049\/jimmunol.1302238","article-title":"Plasma cells in the mucosa of patients with inflammatory bowel disease produce granzyme B and possess cytotoxic activities","volume":"192","author":"Cupi","year":"2014","journal-title":"J Immunol"},{"key":"2021031010464888600_CIT0037","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/ecco-jcc\/jjy203","article-title":"Differences in peripheral and tissue immune cell populations following haematopoietic stem cell transplantation in Crohn\u2019s disease patients","volume":"13","author":"Corraliza","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0038","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/gut.25.1.32","article-title":"Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques","volume":"25","author":"Selby","year":"1984","journal-title":"Gut"},{"key":"2021031010464888600_CIT0039","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/ecco-jcc\/jjaa035","article-title":"Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases","volume":"14","author":"Coletta","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gutjnl-2018-316023","article-title":"Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease","volume":"68","author":"Zeissig","year":"2019","journal-title":"Gut"},{"key":"2021031010464888600_CIT0041","doi-asserted-by":"crossref","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"2009","journal-title":"PLoS One"},{"key":"2021031010464888600_CIT0042","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2011.27","article-title":"Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment","volume":"106","author":"Arijs","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2021031010464888600_CIT0043","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gutjnl-2013-306518","article-title":"Identification of inflammatory mediators in patients with Crohn\u2019s disease unresponsive to anti-TNF\u03b1 therapy","volume":"64","author":"Leal","year":"2015","journal-title":"Gut"},{"key":"2021031010464888600_CIT0044","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of hiv-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Sci Transl Med"},{"key":"2021031010464888600_CIT0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"2021031010464888600_CIT0046","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1083\/jcb.117.1.179","article-title":"Role of integrin alpha 4 beta 7\/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering","volume":"117","author":"R\u00fcegg","year":"1992","journal-title":"J Cell Biol"},{"key":"2021031010464888600_CIT0047","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1749-6632.1998.tb10112.x","article-title":"Fibronectin and integrins in cell adhesion, signaling, and morphogenesis","volume":"857","author":"Miyamoto","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"2021031010464888600_CIT0048","article-title":"\u03b1E\u03b27 integrin identifies subsets of pro-inflammatory colonic CD4+ T lymphocytes in ulcerative colitis","author":"Lamb","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0049","first-page":"1191","article-title":"AlphaE integrin expression is increased in the ileum relative to the colon and unaffected by inflammation","volume":"12","author":"Ichikawa","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2021031010464888600_CIT0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/eji.1830260427","article-title":"Distribution of alpha 4 beta 7 and alpha E beta 7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes","volume":"26","author":"Andrew","year":"1996","journal-title":"Eur J Immunol"},{"key":"2021031010464888600_CIT0051","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(00)70211-3","article-title":"Adhesion molecules expressed on homing lymphocytes in model intestinal epithelia","volume":"118","author":"Shibahara","year":"2000","journal-title":"Gastroenterology"},{"key":"2021031010464888600_CIT0052","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2012.09.020","article-title":"Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets","volume":"38","author":"Sathaliyawala","year":"2013","journal-title":"Immunity"},{"key":"2021031010464888600_CIT0053","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-3083.1995.tb03607.x","article-title":"Expression of the human mucosal lymphocyte antigen, HML-1, by T cells activated with mitogen or specific antigen in vitro","volume":"41","author":"Brew","year":"1995","journal-title":"Scand J Immunol"},{"key":"2021031010464888600_CIT0054","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression levels of 4 genes in colon tissue might be used to predict which patients will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases","volume":"18","author":"Verstockt","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa178\/33966889\/jjaa178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/3\/441\/36463160\/jjaa178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/3\/441\/36463160\/jjaa178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T02:54:11Z","timestamp":1696647251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/3\/441\/5905252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,14]]},"published-print":{"date-parts":[[2021,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa178","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,14]]}}}